Human tetanus immunoglobulin (HTIG)
Sponsors
Zhuhai Trinomab Pharmaceutical Co., Ltd., Sinovac Life Sciences Co., Ltd.
Conditions
Tetanus
Phase 3
Study to Compare the Efficacy and Safety of Passive Immunization With TNM002 Injection and Human Tetanus Immunoglobulin as Prophylaxis Against Tetanus
CompletedNCT05664750
Start: 2022-12-22End: 2023-07-07Updated: 2024-03-08
A Phase Ⅲ Clinical Study of SNA02-48 Injection
Not yet recruitingNCT07633119
Start: 2026-06-28End: 2027-05-31Target: 600Updated: 2026-06-08